Company intelligence / Profile preview

BioGene

Taipei City, Taipei, Taiwan

Ownership: Private
Development stage: Commercial

Overview

BioGene offers high sensitivity RT-qPCR diagnostic testing directly from crude sample mediums (including whole unprocessed blood) without requiring expert personnel, lab facilities, or equipment. Their tests deliver results in under 30 minutes while the patient waits.

Therapeutic areas: Infectious Diseases
Modalities: RT-qPCR diagnostic testing
Industry: Molecular Diagnostics

Drug pipeline

1 asset

afatinib

Commercial

Indications: Esophageal squamous cell carcinoma (ESCC), Non-small cell lung cancer (NSCLC), Gastric cancer

Beyond the preview

Go deeper on BioGene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioGene.

Explore the full profile